💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Vimta Labs Limited is contract research and testing services provider in India. The Company operates through the Contract Research and Testing Services segment. It is engaged in providing a range of services to biopharmaceutical, food, consumer goods, electronic, electrical,…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, fast-growing business, fully valued.
Vimta Labs is scored on the pharma / healthcare framework. It keeps a healthy 14.0% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.48× reported profit. Free cash flow is worth about -0.7% of its market value.
Over the last 3 years revenue compounded at 11%/yr and profit at 24%/yr. Book value itself has compounded 18%/yr — the hallmark of a genuine compounder. Return on equity is a healthy 14.6%. In the latest quarter profit grew 41% versus the prior quarter.
At 27× earnings, the stock sits at the 78th percentile of its own 5.2-year range — the expensive end of where it has historically traded. Today's price implies ~17%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 34.83 | — | — |
| P/B | 6.24 | 4.11 | worse |
| EV/EBITDA | 18.28 | 19.15 | better |
| ROE | 14.59 | — | — |
| ROCE | 19.04 | 6.87 | better |
| ROA | 13.94 | — | — |
| Quick Ratio | 2.46 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue is on a 2-year growth streak. 11% CAGR over 3 years — steady double-digit compounder. Growth is decelerating — latest year grew slower than the year before.
Profit is on a 2-year growth streak. Profit is growing faster than revenue (24% vs 11%) — margin expansion is at work.
Operating margin has expanded from 13% to 21% — the business is keeping more of each rupee earned. The gap between operating and net margin is widening — interest or tax costs are rising.
ROE at 13% — a respectable return on shareholder capital.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. 24% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.5× PAT — earnings are well-backed by cash; strong accrual quality. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 7% sequentially — momentum is building. Run-rate stepping up — recent quarters average 13% above earlier ones.
Profit jumped 41% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (15% → 24%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 5.2y median.
Promoters at 35.6% — dispersed ownership; institutional flows drive the stock.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.